Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 185

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

BCL9 Promotes Tumor Progression by Conferring Enhanced Proliferative, Metastatic, and Angiogenic Properties to Cancer Cells

Open access
Mani, Mala, Carrasco, Daniel E., Zhang, Yunyu, Takada, Kohichi, Gatt, Moshe E., Dutta-Simmons, Jui, Ikeda, Hiroshi, Diaz-Griffero, Felipe, Pena-Cruz, Victor, Bertagnolli, Monica, Myeroff, Lois L., Markowitz, Sanford D., Anderson, Kenneth C., Carrasco, Daniel R. · 2009 · Cancer Research

Abstract

Several components of the Wnt signaling cascade have been shown to function either as tumor suppressor proteins or as oncogenes in multiple human cancers, underscoring the relevance of this pathway in oncogenesis and the need for further investigation of Wnt signaling components as potential targets for cancer therapy. Here, using expression profiling analysis as well as in vitro and in vivo functional studies, we show that the Wnt pathway component BCL9 is a novel oncogene that is aberrantly expressed in human multiple myeloma as well as colon carcinoma. We show that BCL9 enhances β-catenin–mediated transcriptional activity regardless of the mutational status of the Wnt signaling components and increases cell proliferation, migration, invasion, and the metastatic potential of tumor cells by promoting loss of epithelial and gain of mesenchymal-like phenotype. Most importantly, BCL9 knockdown significantly increased the survival of xenograft mouse models of cancer by reducing tumor load, metastasis, and host angiogenesis through down-regulation of c-Myc, cyclin D1, CD44, and vascular endothelial growth factor expression by tumor cells. Together, these findings suggest that deregulation of BCL9 is an important contributing factor to tumor progression. The pleiotropic roles of BCL9 reported in this study underscore its value as a drug target for therapeutic intervention in several malignancies associated with aberrant Wnt signaling. [Cancer Res 2009;69(19):7577–86]

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-09-0773

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 185

Metadata

Authors
Mani, M., Carrasco, D. E., Zhang, Y., Takada, K., Gatt, M. E., Dutta-Simmons, J., Ikeda, H., Diaz-Griffero, F., Pena-Cruz, V., Bertagnolli, M., Myeroff, L. L., Markowitz, S. D., Anderson, K. C., & Carrasco, D. R.
Venue
Cancer Research
Published
2009-10-01
Volume
69
Issue
19
Pages
7577-7586
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2143311031
Cited by
185
References
4
FWCI
3.00
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BCL9 Promotes Tumor Progression by Conferring Enhanced Proliferative, Metastatic, and Angiogenic Properties to Cancer Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-09-0773
The paper
Mani, M., Carrasco, D. E., Zhang, Y., Takada, K., Gatt, M. E., Dutta-Simmons, J., Ikeda, H., Diaz-Griffero, F., Pena-Cruz, V., Bertagnolli, M., Myeroff, L. L., Markowitz, S. D., Anderson, K. C., & Carrasco, D. R. (2009). BCL9 Promotes Tumor Progression by Conferring Enhanced Proliferative, Metastatic, and Angiogenic Properties to Cancer Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-09-0773

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.